Journal PoliciesLinks to Sections
Scope of the Journal
Deposition of Sequence and Microarray Data
Peer review process
SCOPE OF THE JOURNAL
International Health publishes original, peer-reviewed articles and reviews reflecting healthcare delivery and analysis in the field of global medicine and health. It will be of particular interest to those tasked with the delivery of care to communities where resources are extremely limited.
Original Articles and Short Communications
These reflect healthcare delivery and analysis in the field of global medicine and international health. They will be of interest to those tasked with the delivery of care to communities where resources are extremely limited. We particularly welcome papers which relate to the development of healthcare systems worldwide:
- Evaluation of disease control programmes
- Health systems research
- Social aspects of disease both communicable and non-communicable
- Economic aspects of disease both communicable and non-communicable
- Management of healthcare
- Economics of healthcare
- Health policy
These are similar to original articles but do not include sufficient new information to warrant a full-length article. The Results and Discussion sections can be combined if appropriate.
These set in context and illustrate the significance of articles published in International Health and are usually written as a result of a specific invitation. The Editor may invite commentaries on other topics that highlight developments in tropical medicine and international health; for example commentaries can:
- highlight and set in context a recent discovery
- critically appraise established information and ideas
- illustrate how established information and ideas can be relevant in a new context
- show how established policy in international health and tropical medicine may have unintended consequences.
These give an authoritative account of an aspect of tropical medicine and international health. The intention is that these reviews will provide the readers with an insight into topics of current interest and to widen the scope of the journal to bring to the attention of readers emerging diseases and other developing aspects of International Health. Reviews do not recapitulate material found in postgraduate textbooks.
We no longer print correspondence. Instead, readers have the opportunity to respond to any of the articles in the journal online in the form of an E-letter. This offers an opportunity for feedback, debate and the promotion of ideas for future articles. To submit a comment responding to a particular article: Click on the link 'Responses: Submit a response' in the box on the right hand side of the article. To read comments responding to a particular article: Click on the link 'Responses: Read responses' in the box on the right hand side of the article.
Authors should observe high standards with respect to publication ethics as set out by the Commission on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE). Falsification or fabrication of data, plagiarism, including duplicate publication of the authors’ own work without proper citation, and misappropriation of the work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with the COPE guidelines.
All authors listed on the manuscript should have contributed significantly to the experimental design, its implementation, or analysis and interpretation of the data. All authors should have been involved in the writing of the manuscript at draft and any revision stages, and have read and approved the final version. Anyone who made major contributions to the writing of the manuscript should be listed as an author (e.g. “ghost writing” is prohibited by the Journal). Any other individuals who made less substantive contributions to the experiment or the writing of the manuscript should be listed in the acknowledgement section. Authors should obtain permission to acknowledge from all those named in the Acknowledgements and forward details of this permission to the editorial office at the time of submission. Any change in authorship (including author order) after the initial manuscript submission must be approved in writing by all authors.
Please use the following format (use initials to refer to each author's): CJ and HGM conceived the study; BJA and CJ designed the study protocol; BJA and HGM carried out the clinical assessment; CJ and FT carried out the immunoassays and cytokine determination, and analysis and interpretation of these data. BJA and CJ drafted the manuscript; BJA HGM and FT critically revised the manuscript for intellectual content. All authors read and approved the final manuscript. BJA and CJ are guarantors of the paper.
Authorship and 'Umbrella' groups
Many large collaborative studies are organized under a group name which represents all the participants. All articles must have at least one named individual as author. Authors who wish to acknowledge the umbrella group from which the data originate should first list the author(s) of the article and follow this with 'on behalf of the GROUP NAME'. If necessary, the names of the participants may be listed in the Acknowledgements section.
By submitting your manuscript to the Journal it is understood that this it is an original manuscript, is unpublished work and is not under consideration elsewhere. Plagiarism, including duplicate publication of the author’s own work, in whole or in part without proper citation is not tolerated by the Journal. Manuscripts submitted to the Journal may be checked for originality using anti-plagiarism software.
Conflicts of interest
At the point of submission, each author should reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated – including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition. When considering whether you should declare a conflicting interest or connection please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it?
As part of the online submission process, corresponding authors are required to confirm whether they or their co-authors have any Conflicts of Interest to declare, and to provide details of these. If the Corresponding author is unable to confirm this information on behalf of all co-authors, please contact the Editorial Office. It is the Corresponding author’s responsibility to ensure that all authors adhere to this policy.
If the manuscript is published, Conflict of Interest information, including if none was declared, will be communicated in a statement in the published paper.
We encourage authors to use the following tools to ensure good practice in reporting their work:
- The CONSORT checklist of items to include when reporting randomised trials;
- The STARD checklist of items for reporting studies on diagnostic accuracy;
- The PRISMA checklist for systematic reviews and meta-analyses.
When reporting animal experiments, authors should indicate whether the institution’s, national research council’s, or any other law on the care and use of laboratory animals was followed.
When reporting on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association. Manuscripts should include a statement that the patient’s written consent was obtained and any information, including illustrations, should be as anonymized as far as possible. Authors should indicate that the design of the work has been approved by local ethical committees or that it conforms to standards currently applied in the country of origin. The name of the authorizing body should be stated in the paper.
DEPOSITION OF SEQUENCE AND MICROARRAY DATA
Nucleotide and protein sequences
If a manuscript reports on any new nucleotide or protein sequences, these must be deposited in a publicly available database at the time of submission.
Nucleotide sequences should be deposited in one of the three major collaborative databases – EMBL, GenBank, or DDBJ. New sequences and their accession numbers should be listed below the abstract and cited within the text. Please see the Manuscript Preparation Instructions page for more information.
Protein sequences should be deposited with UniProt.
Authors submitting microarray data should comply with the ‘Minimal Information About a Microarray Experiment’ (MIAME) guidelines. Microarray data should also be submitted to GEO (http://www.ncbi.nlm.nih.gov/geo/) or ArrayExpress (http://www.ebi.ac.uk/arrayexpress) and to provide accession numbers by the time the paper is accepted.
Registering clinical trials
In accordance with the Clinical Trial Registration Statement from the International Committee of Medical Journal Editors (ICMJE) all clinical trials published in the Journal must be registered in a public trials registry at or before the onset of participant enrolment. For any clinical trials commencing prior to 2008, retrospective registration will be accepted.
The registry must be accessible to the public at no charge, searchable, open to all prospective registrants, managed by a not-for-profit organization, and include all the necessary information as specified by the ICMJE. A list of recommended registries can be found on the ICMJE website. Results posted in the same clinical trials registry in which the primary registration resides will not be considered prior to publication if they are presented in the form of a brief abstract (<500 words or less) or a table.
Authors are requested to provide the exact URL and unique identification number for the trial registration at the time of submission. This information will be published in the article and we ask that you include the URL and identification number on the title page of your manuscript.
Reporting clinical trials
Clinical trials should comply with the Consolidated Standards of Reporting Trials Statement (CONSORT), which is available here. Authors reporting on randomized clinical trials (RCT) should consult the CONSORT checklist when preparing their manuscripts. All RCT data will be evaluated in accordance with the rules and checklist of the CONSORT statement.
Other types of studies should follow guidelines where available. These include STARD (Standards for the Reporting of Diagnoistic accuracy studies), STROBE (Strengthening the reporting of observational studies in epidemiology), PRISMA (Transparent Reporting of Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analyses of observational studies). For further information on good reporting of health research studies please go to the EQUATOR network.
PEER REVIEW PROCESS
All submissions to the Journal are initially reviewed by the editorial team. At this stage manuscripts may be rejected without peer review if it is felt that they are not of high enough priority or not relevant to the Journal. This fast rejection process means that authors are given a quick decision and do not need to wait for the review process.
Manuscripts that are not instantly rejected are sent out for peer review, usually to two independent reviewers. Based on the feedback from these reviewers a decision is given on the manuscript.
Manuscripts may also be sent out for statistical review.
If you believe that your manuscript has been incorrectly rejected by the editorial team, authors may send an appeal to the editorial office. To submit an appeal please send an email to the editorial office giving as much detail as possible about why you believe that your manuscript has been incorrectly rejected. Please do not re-submit your article.
For information about this Journal's policy, please visit our Author Self-Archiving policy page here.
The mention of trade names, commercial products or organizations, and the inclusion of advertisements in International Health does not imply endorsement by the Society, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work and clinical findings published in International Health. The ultimate responsibility for the use and dosage of drugs mentioned in International Health and in the interpretation of published material lies with the medical practitioner, and the editors and publishers cannot accept liability for damages arising from any errors or omissions in International Health. Please inform the editors of any errors.
The opinions expressed in International Health are those of the authors and contributors, and do not necessarily reflect those of the Society, or the editorial board, Oxford University Press or the organization to which the authors are affiliated.
- About the journal
- Rights & permissions
- Dispatch date of the next issue
- We are mobile - find out more
- Dengue fever
- Developments in travel medicine
- Discovery and delivery of new paradigms in global health
- Emerging infectious diseases
- Health in Humanitarian Settings
- Hepatitis in high-risk groups
- HIV: Access and monitoring of treatment
- International Health Open Access articles
- Measuring Progress
- Presidential addresses of the RSTMH
- Vector-borne diseases